Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Additional information

Ziegler Bottoms are characterized as comprising of two primary constituents; icosan-1-ol and docosan-1-ol. Together these constituents represent a structural class of components (alcohols) that constitute approximately 82% of the composition of Ziegler Bottoms. Study data, where available, for each of these primary constituents has been evaluated and considered together. In a conservative approach the most sensitive study result from across the two constituents has been identified and used to address the endpoint in question. 

A key reliable (Klimisch 2) Ames study was conducted with docosan-1-ol in S. typhimurium strains TA 98, TA100, TA1535, TA1537 and TA 1538. This study was conducted following a protocol similar to OECD 471 but with some deviations (e.g. No TA102 or E. coli WP2 uvrA; 2-aminoanthracene only positive control with metabolic activation). This study reported that docosan1-ol was negative in this bacterial mutation assay. Study data from this study was used as read-across data to support the equivalent icosan-1-ol endpoint.

A second key study reported on a reliable (Klimisch 2) in vitro mammalian chromosome aberration test conducted with a protocol very similar to OECD guideline 473 with docoasn-1-ol. Docosan-1-ol did not increase the incidence of chromosome aberrations in Chinese hamster V79 cells in the presence or absence of metabolising fraction at concentrations up to 20 µg/ml. There was no evidence of cytotoxicity at this dose level.Study data from this study was used as read-across data to support the equivalent icosan-1-ol endpoint.

In a reliable (Klimisch 2) micronucleus assay conducted according to a procotol similar to OECD 474 the in vivo mutagenicity of docosan-1-ol was assessed. In this study docosan-1-ol did not increase the incidence of micronuclei in mouse bone marrow cells after a single oral gavage dose of up to 500 mg/kg bw. Consequently docosan-1-ol was reported to be negative in this assay. Study data from this study was used as read-across data to support the equivalent icosan-1-ol endpoint.

On the basis of the genetic toxicity information included as part of this submission and in line with the read-across justification included, Ziegler Bottoms are considered not to be genotoxic.


Short description of key information:
In vitro:
Gene mutation (Bacterial reverse mutation assay / Ames test): Docosan-1-ol was negative with and without activation in S. typhimurium strains TA 98, TA100, TA1535, TA1537 and TA 1538 (OECD TG 471)
Cytogenicity in mammalian cells: Docosan-1-ol was negative with and without activation in Chinese hamster ovary cells (similar to OECD TG 473)
Mutagenicity in mammalian cells: Docosan-1-ol was negative with and without activation in Chinese hamster lung V79 cells (similar to OECD TG 476)

In vivo:
Mouse micronucleus study: Docosan-1-ol was negative in bone marrow (similar to OECD TG 474)

Endpoint Conclusion: No adverse effect observed (negative)

Justification for classification or non-classification

These findings do not warrant the classification of Ziegler Bottoms as genotoxic under the new Regulation (EC) 1272/2008 on classification, labelling and packaging of substances and mixtures (CLP) and under the Directive 67/518/EEC for dangerous substances and Directive 1999/45/EC for preparations.